Abstract:Background During the last decades, there have been substantial improvements in treatment techniques for percutaneous coronary intervention (PCI). Yet, in-stent restenosis (ISR) continues to pose significant challenges as they account for 10% of all PCI cases and are associated with worse outcome compared to de-novo lesions. When assessing ISR with PCI, balloon angioplasty with drug-coated balloons (DCB) is frequently used. Purpose Despite frequent use of DCB, there is a lack of long-term data ensuring the safety of DCB for ISR as no randomized trial has extended beyond a 3-year follow-up. We aimed to study the long-term outcome and conducted a nationwide three-arm investigation on the outcome of ISR, comparing DCB with drug-eluting stents (DES) or plain old balloon angioplasty (POBA) within a 5-year follow-up. Methods We conducted a nationwide analysis using the SWEDEHEART (Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) registry. The SWEDEHEART registry was used to include any ISR undergoing coronary angiography between June 11, 2013, and December 31, 2020. Target lesion revascularization (TLR) was the primary outcome. Secondary outcomes included all-cause mortality, myocardial infarction, and any PCI. The outcomes were analysed using a multivariable Cox regression model. Results A total of 9304 segments from 7987 patients were eligible. Compared to POBA, the use of DCB was associated with lower rates of TLR, hazard ratio (HR) 0.62 (95% confidence interval [CI]: 0.50-0.78), all-cause mortality, HR 0.60 (95% CI: 0.50-0.72), and any PCI, HR 0.78 (95% CI: 0.66-0.93). No difference was observed for myocardial infarction. Compared to DES, the use of DCB was associated with higher rates of TLR, HR 1.24 (95% CI: 1.08-1.42). No difference was observed for all-cause mortality, cardiovascular mortality, myocardial infarction, or any PCI. Conclusions In this nationwide analysis including any ISR undergoing PCI, the use of DCB showed superior outcomes compared to POBA within 5 years but higher rates of repeat revascularizations compared to DES. While DES demonstrated lower TLR rates than DCB, the lack of mortality differences indicates that DCB is a viable option, particularly for patients where DES might not be suitable, but that DES should be considered as the first line strategy.Table 1.5-year outcomeFigure 1.Kaplan-Meier curves

Outcomes of Drug Eluting Balloons for In-Stent Restenosis: Large Cohort Analysis and Single Center Clinical Experience

Drug-eluting Balloons Versus Drug-Eluting Stents for the Management of In-Stent Restenosis: A Meta-Analysis of Randomized and Observational Studies

Biolimus-coated Versus Paclitaxel-Coated Balloons for Coronary In-Stent Restenosis (BIO ASCEND ISR): a Randomised, Non-Inferiority Trial.

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis.

Comparative outcomes of drug-coated balloon angioplasty versus second-generation drug-eluting stent for in-stent restenosis: a real-world data analysis

EFFICACY AND SAFETY OF DRUG-ELUTING BALLOON VS DRUG-ELUTING STENTS IN THE TREATMENT OF IN-STENT RESTENOSIS

Long-term outcomes following DCB vs. DES for ISR treatment

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

Long-Term Outcomes Following Sirolimus-Coated Balloon or Drug-Eluting Stents for Treatment of In-Stent Restenosis

Percutaneous coronary intervention of in-stent restenosis: A three-arm analysis from SWEDEHEART

Drug-eluting balloons for de novo coronary artery disease: a meta-analysis of angiographic and clinical data.

Management of Distal/bifurcation Left Main Restenosis after Drug Eluting Stents Implantation: Single Center Experience.

Long-Term Follow-Up after Treatment of Drug-Eluting Stent Restenosis and De Novo Lesions Using SeQuent Please Paclitaxel-Coated Balloons

Drug-eluting balloon for treatment of in-stent restenosis after carotid artery stenting: preliminary report

Efficacy and Safety of Drug-Eluting Stent Implantation for the Treatment of In-Stent Restenosis Occurring Within Bare-Metal Stent and Drug-Eluting Stent

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials

Comparison of Drug-Coated Balloons With Drug-Eluting Stents in Patients With In-Stent Restenosis: A Systematic Review and Meta-Analysis

GW24-e0345 Drug-eluting Balloons Forde Novocoronary Artery Disease: Pooled Angiographic and Clinical Data

Drug-eluting balloons versus drug-eluting stents for small vessel coronary artery disease: a meta-analysis.

Long‐term outcomes of DCB and DES for the treatment of in‐stent restenosis in relation to the vessel size

Drug‐eluting Balloons for De Novo Coronary Artery Disease